Hepatic metabolism represents the most important pathway for elimination of many drugs given to children. Although there are more than 50 million children in the United States and almost all receive some form of drug therapy during childhood, many aspects of hepatic drug clearance have not been well characterized in children. The research will will undertake in the continuation of this program is aimed at two major aspects of hepatic drug metabolism in children; (1) disease and treatment related changes in hepatic drug clearance in children with leukemia and (2) genetic polymorphic drug metabolism in children with and without cancer. Cancer remains the leading cause of death by disease in U.S. children over 2 years of age, and leukemia is one of the most common and curable types of childhood cancer. The first major aspect of our research is aimed at determining whether the administration of anticancer drugs to children with acute lymphocytic leukemia has significant effects on drug disposition, particularly hepatic clearance and protein binding. Three model substrates (antipyrine, lorazepam and ICG) are used to assess three major processes involved in hepatic drug clearance and to evaluate treatment-or diseased-induced changes within the same child. As more than 50% of these children are now cured of acute lymphocytic leukemia and we have shown that interpatient differences in drug clearance influence therapeutic response, these studies are important for several reasons. The second major aim of our research is to evaluate the expression of genetically determined polymorphic drug oxidation and N-acetylation in children with and without cancer. Pediatric polymorphic drug metabolism studies have never been done to assess and-related expression of genotype and whether children who develop cancer are different from children who do not develop cancer. Two studies in adults with lung cancer and bladder carcinoma indicate that drug oxidation or N-acetylation phenotype may be different in patients who develop cancer, however, this has never been assessed in pediatric cancer patients. We will use two model substrates (dextromethorphan and caffeine) to determine oxidation and acetylation phenotype in children with cancer and a matched control group of healthy children without cancer. Molecular studies will also be undertaken to determine if structural defects in the genome can be detected which are associated with metabolic phenotype. Collectively, this research will add considerable new knowledge to our understanding of drug metabolism in children.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37CA036401-07
Application #
3482346
Study Section
Pharmacology A Study Section (PHRA)
Project Start
1984-07-01
Project End
1992-05-31
Budget Start
1990-06-01
Budget End
1991-05-31
Support Year
7
Fiscal Year
1990
Total Cost
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Diouf, Barthelemy; Lin, Wenwei; Goktug, Asli et al. (2018) Alteration of RNA Splicing by Small-Molecule Inhibitors of the Interaction between NHP2L1 and U4. SLAS Discov 23:164-173
Pui, Ching-Hon (2018) To delay or not to delay, that is the question for patients with acute lymphoblastic leukemia who do not receive prophylactic cranial irradiation. Cancer 124:4442-4446
Diouf, Barthelemy; Evans, William E (2018) Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy: Progress Continues. Clin Pharmacol Ther :
Li, Jian-Feng; Dai, Yu-Ting; Lilljebjörn, Henrik et al. (2018) Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases. Proc Natl Acad Sci U S A 115:E11711-E11720
Heikamp, Emily B; Pui, Ching-Hon (2018) Next-Generation Evaluation and Treatment of Pediatric Acute Lymphoblastic Leukemia. J Pediatr 203:14-24.e2
Dvorak, Christopher C; Satwani, Prakash; Stieglitz, Elliot et al. (2018) Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. Pediatr Blood Cancer 65:e27034
Karol, S E; Larsen, E; Cheng, C et al. (2017) Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemia. Leukemia 31:1325-1332
Liu, C; Yang, W; Pei, D et al. (2017) Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait. Clin Pharmacol Ther 101:373-381
Landier, Wendy; Hageman, Lindsey; Chen, Yanjun et al. (2017) Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1. J Clin Oncol 35:1730-1736
Liu, Y; Fernandez, C A; Smith, C et al. (2017) Genome-Wide Study Links PNPLA3 Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy. Clin Pharmacol Ther 102:131-140

Showing the most recent 10 out of 258 publications